5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAF V600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study.

Paolo Antonio AsciertoBrigitte DrénoJames LarkinAntoni RibasGabriella LiszkayMichele MaioMario MandalàLev DemidovDaniil StroyakovskiyLuc ThomasLuis de la Cruz-MerinoVictoria AtkinsonCaroline DutriauxClaus GarbeJessie HsuSurai JonesHaocheng LiEdward McKennaAthina VoulgariGrant A McArthur

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

Extended follow-up of coBRIM confirms the long-term clinical benefit and safety profile of cobimetinib plus vemurafenib compared with vemurafenib monotherapy in patients with BRAF V600 mutation-positive advanced melanoma.

Keyphrases

metastatic colorectal cancer
skin cancer
type diabetes
open label
randomized controlled trial
combination therapy
clinical trial
basal cell carcinoma
weight loss
glycemic control